Survey on the Pharmacy Follow-up of Alli Purchasers

Overweight Clinical Trial

Official title:

Survey on the Pharmacy Follow up of Alli Purchasers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01387243
• Other study ID #: W5350856
• Status: Completed
• Phase: N/A
• First received: March 29, 2010
• Last updated: October 25, 2012
• Start date: January 2010
• Est. completion date: December 2010

Study information

• Verified date: October 2012
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

To assess the feasibility and acceptability of genuine pharmacy follow up of people wishing to lose weight.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Individuals who have been recognized as being eligible for treatment, who have agreed to pharmacy follow up, and have given their informed consent to take part in the survey.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Overweight

Intervention

Drug:
• Orlistat
60 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Physical activity		baseline to 1 year	No
Secondary	Change in dietary behavior		baseline to 1 year	No
Secondary	Evaluation of care pathway (e.g., consultation with doctors, use of nutritional information)		baseline to 1 year	No
Secondary	Satisfaction with management (i.e., results on weight and treatment comfort)		baseline to 1 year	No